中国中医药信息杂志Issue(10)：54-59,6.DOI:10.3969/j.issn.1005-5304.2015.10.016
黄芩苷和牛磺酸对阿尔茨海默病大鼠保护作用的最佳配比研究
Research on Optimal Combination Proportion of Protective Effects of Combined Baicalin and Taurine in Alzheimer’s Disease Rats
摘要
Abstract
Objective To observe the best compatibility proportion and action mode of protective effects of combined baicalin and taurine in Alzheimer’s disease (AD) model.Methods Aβ1-42 was injected through lateral ventricles to establish AD rat models. SD rats were randomly divided into sham-operation group, model group, aricept group, combined baicalin and taurine in different proportions group. Administration groups were treated with different medicines, while sham-operation group and model group were treated with the same amount of normal saline for 40 days. The step-through latency and the times of mistakes were detected through step-through test;the escape latent and the times of crossing target quadrant were detected through Morris water maze. Furthermore, the human neuroblastoma SH-SY5Y cells were induced by 5 µmol/L Aβ1-42 for establishing a cellular AD model. The AD cellular model was treated with baicalin and taurine compatibility in different proportions for 48 hours. Then the rate of cell viability was detected by MTT assay, and the median effective concentration (EC50) and combination index were calculated. Results Baicalin and taurine in 2∶1 and 1∶1 proportion groups can significantly improve learning and memory ability in AD rats (P<0.05,P<0.01). The EC50 were 2.110 µmol/L and 0.422 µmol/L, respectively. The combination index was 0.308.Conclusion Baicalin combined with taurine exhibit synergetic protective effects in AD rats induced by Aβ1-42. The optimal compatibility proportion of baicalin and taurine is 2∶1, and EC50 is 0.279 µmol/L.关键词
黄芩苷/牛磺酸/阿尔茨海默病/协同作用/最佳配伍比例/大鼠Key words
baicalin/taurine/Alzheimer's disease/synergistic effect/optimal compatibility proportion/rats分类
医药卫生引用本文复制引用
武义明,赵军,马涛,张占军,白卫国,卫东锋..黄芩苷和牛磺酸对阿尔茨海默病大鼠保护作用的最佳配比研究[J].中国中医药信息杂志,2015,(10):54-59,6.基金项目
国家科技重大专项-重大新药创制(2013ZX09103002-002、2013ZX09301307)；国家自然科学基金(81274001、81430100)；中国中医科学院基本科研业务费自主选题项目(Z0288) （2013ZX09103002-002、2013ZX09301307）
